Search Within

Gilles Andre Salles

Formats
  1. Meeting Abstract (182)
  2. Journal Article (79)
  3. Research Letter (18)
  4. Review (18)
  5. Editorial (5)
  6. Correspondence (3)
  7. Conference Paper (2)
  8. Guidelines (2)
  9. Book Section (1)
Groups
  1. Department of Medicine (310)
  2. Hematologic Malignancies, Division of (310)
  3. Center for Hematologic Malignancies (168)
  4. Lymphoma (164)
  5. Hematology-Oncology Fellows (141)
  6. Survivorship Research (118)

More Groups

People
  1. Maria Palomba (112)
  2. Andrew Zelenetz (76)
  3. Anita Kumar (66)
  4. Lorenzo Falchi (66)
  5. Gunjan Shah (63)
  6. Miguel-Angel Perales (60)

More People

Years
  1. 2025 (26)
  2. 2024 (68)
  3. 2023 (97)
  4. 2022 (69)
  5. 2021 (44)
  6. 2020 (6)
Publications
  1. Blood (127)
  2. Hematological Oncology (28)
  3. Journal of Clinical Oncology (18)
  4. Blood Advances (16)
  5. Haematologica (15)
  6. British Journal of Haematology (10)

More Publications

Publishers
  1. American Society of Hematology (144)
  2. Wiley Blackwell (30)
  3. Elsevier Inc. (21)
  4. American Society of Clinical Oncology (18)
  5. Ferrata Storti Foundation (15)
  6. Nature Publishing Group (14)

More Publishers

Results (310)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Idelalisib immune-related toxicity is associated with improved treatment response
    Journal Article

    Wagner-Johnston, N. D.; Sharman, J.; Furman, R. R.; Salles, G.; Brown, J. R.; Robak, T.; Gu, L.; Xing, G.; Chan, R. J.; Rajakumaraswamy, N.; more...
    Leukemia and Lymphoma (2021)

    Fulltext@MSK | Save
  • Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: Is 4 Gy suitable for curable patients?
    Journal Article

    Imber, B. S.; Chau, K. W.; Lee, J.; Lee, J.; Casey, D. L.; Yang, J. C.; Wijentunga, N. A.; Shepherd, A.; Hajj, C.; Qi, S.; more...
    Blood Advances (2021)

    Fulltext@MSK | Save
  • Overall survival with tafasitamab + lenalidomide (LEN) vs routinely administered therapies for ASCT-ineligible relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Outcomes from the observational RE-MIND2 study
    Meeting Abstract

    Nowakowski, G. S.; Yoon, D. H.; Mondello, P.; Joffe, E.; Peters, A.; Fleury, I.; Greil, R.; Ku, M.; Marks, R.; Kim, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials
    Review

    Westin, J. R.; Kersten, M. J.; Salles, G.; Abramson, J. S.; Schuster, S. J.; Locke, F. L.; Andreadis, C.
    American Journal of Hematology (2021)

    Fulltext@MSK | Save
  • Primary refractory follicular lymphoma: A poor outcome entity with high risk of transformation to aggressive B cell lymphoma
    Journal Article

    Alonso-Álvarez, S.; Manni, M.; Montoto, S.; Sarkozy, C.; Morschhauser, F.; Wondergem, M. J.; Guarini, A.; Magnano, L.; Alcoceba, M.; Chamuleau, M.; more...
    European Journal of Cancer (2021)

    Fulltext@MSK | Save
  • Follicular lymphoma triggers phenotypic and functional remodeling of the human lymphoid stromal cell landscape
    Journal Article

    Mourcin, F.; Verdière, L.; Roulois, D.; Amin, R.; Lamaison, C.; Sibut, V.; Thamphya, B.; Pangault, C.; Monvoisin, C.; Huet, S.; more...
    Immunity (2021)

    Fulltext@MSK | Save
  • The use of tafasitamab in diffuse large B-cell lymphoma
    Review

    Düll, J.; Topp, M.; Salles, G.
    Therapeutic Advances in Hematology (2021)

    Fulltext@MSK | Save
  • Role of maintenance rituximab after first‐line bendamustine + rituximab or R‐CHOP in patients with mantle cell lymphoma from a large US real‐world cohort
    Meeting Abstract

    Wang, M.; Salles, G.; Kumar, A.; Qi, K.; Daly, K.; Parisi, L.; Zhu, A.; Martin, P.
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Real‐world treatment patterns and outcomes of 3455 previously untreated mantle cell lymphoma patients in US routine clinical practice
    Meeting Abstract

    Kumar, A.; Martin, P.; Wang, M.; Qi, K.; Daly, K.; Parisi, L.; Zhu, A.; Salles, G.
    Hematological Oncology (2021)

    Fulltext@MSK | Save